- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- DIVIS LABORATORIES - CIPLA
DIVIS LABORATORIES vs CIPLA - Comparison Results
DIVIS LABORATORIES 
Change
Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More
CIPLA
Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
Current Valuations
| DIVIS LABORATORIES | CIPLA | DIVIS LABORATORIES/ CIPLA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 38.4 | 40.5 | 94.9% | View Chart |
| P/BV | x | 6.2 | 3.7 | 167.3% | View Chart |
| Dividend Yield | % | 0.7 | 0.5 | 158.2% |
Financials
 DIVIS LABORATORIES  CIPLA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DIVIS LABORATORIES Mar-18 |
CIPLA Mar-18 |
DIVIS LABORATORIES/ CIPLA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,142 | 663 | 172.2% | |
| Low | Rs | 533 | 479 | 111.3% | |
| Sales per share (Unadj.) | Rs | 146.6 | 189.0 | 77.5% | |
| Earnings per share (Unadj.) | Rs | 33.0 | 17.6 | 187.8% | |
| Cash flow per share (Unadj.) | Rs | 38.4 | 34.0 | 112.9% | |
| Dividends per share (Unadj.) | Rs | 10.00 | 3.00 | 333.3% | |
| Dividend yield (eoy) | % | 1.2 | 0.5 | 227.3% | |
| Book value per share (Unadj.) | Rs | 222.8 | 176.7 | 126.1% | |
| Shares outstanding (eoy) | m | 265.47 | 805.12 | 33.0% | |
| Bonus/Rights/Conversions | - | ESOP | - | ||
| Price / Sales ratio | x | 5.7 | 3.0 | 189.1% | |
| Avg P/E ratio | x | 25.3 | 32.5 | 78.1% | |
| P/CF ratio (eoy) | x | 21.8 | 16.8 | 129.9% | |
| Price / Book Value ratio | x | 3.8 | 3.2 | 116.3% | |
| Dividend payout | % | 30.3 | 17.1 | 177.5% | |
| Avg Mkt Cap | Rs m | 222,318 | 459,724 | 48.4% | |
| No. of employees | `000 | 10.8 | 23.6 | 45.6% | |
| Total wages/salary | Rs m | 4,561 | 26,901 | 17.0% | |
| Avg. sales/employee | Rs Th | 3,616.0 | 6,446.1 | 56.1% | |
| Avg. wages/employee | Rs Th | 423.8 | 1,139.4 | 37.2% | |
| Avg. net profit/employee | Rs Th | 814.9 | 600.0 | 135.8% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 38,915 | 152,193 | 25.6% | |
| Other income | Rs m | 1,134 | 3,577 | 31.7% | |
| Total revenues | Rs m | 40,049 | 155,769 | 25.7% | |
| Gross profit | Rs m | 12,617 | 28,264 | 44.6% | |
| Depreciation | Rs m | 1,425 | 13,228 | 10.8% | |
| Interest | Rs m | 13 | 1,142 | 1.2% | |
| Profit before tax | Rs m | 12,313 | 17,470 | 70.5% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | -28 | 0.0% | |
| Extraordinary Inc (Exp) | Rs m | 0 | -775 | 0.0% | |
| Tax | Rs m | 3,543 | 2,501 | 141.7% | |
| Profit after tax | Rs m | 8,770 | 14,166 | 61.9% | |
| Gross profit margin | % | 32.4 | 18.6 | 174.6% | |
| Effective tax rate | % | 28.8 | 14.3 | 201.0% | |
| Net profit margin | % | 22.5 | 9.3 | 242.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 45,351 | 108,141 | 41.9% | |
| Current liabilities | Rs m | 6,507 | 38,322 | 17.0% | |
| Net working cap to sales | % | 99.8 | 45.9 | 217.6% | |
| Current ratio | x | 7.0 | 2.8 | 247.0% | |
| Inventory Days | Days | 127 | 97 | 130.6% | |
| Debtors Days | Days | 95 | 74 | 127.9% | |
| Net fixed assets | Rs m | 21,160 | 109,411 | 19.3% | |
| Share capital | Rs m | 531 | 1,610 | 33.0% | |
| "Free" reserves | Rs m | 58,625 | 140,682 | 41.7% | |
| Net worth | Rs m | 59,156 | 142,292 | 41.6% | |
| Long term debt | Rs m | 0 | 36,621 | 0.0% | |
| Total assets | Rs m | 67,832 | 228,606 | 29.7% | |
| Interest coverage | x | 926.8 | 16.3 | 5,688.2% | |
| Debt to equity ratio | x | 0 | 0.3 | 0.0% | |
| Sales to assets ratio | x | 0.6 | 0.7 | 86.2% | |
| Return on assets | % | 12.9 | 6.7 | 193.4% | |
| Return on equity | % | 14.8 | 10.0 | 148.9% | |
| Return on capital | % | 20.8 | 10.0 | 209.3% | |
| Exports to sales | % | 0 | 32.8 | 0.0% | |
| Imports to sales | % | 21.8 | 0 | - | |
| Exports (fob) | Rs m | NA | 49,883 | 0.0% | |
| Imports (cif) | Rs m | 8,485 | NA | - | |
| Fx inflow | Rs m | 32,359 | 51,691 | 62.6% | |
| Fx outflow | Rs m | 9,042 | 21,033 | 43.0% | |
| Net fx | Rs m | 23,317 | 30,658 | 76.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 7,759 | 14,628 | 53.0% | |
| From Investments | Rs m | -4,783 | -8,540 | 56.0% | |
| From Financial Activity | Rs m | -3,142 | -3,855 | 81.5% | |
| Net Cashflow | Rs m | -166 | 2,431 | -6.8% | |
Share Holding
| Indian Promoters | % | 52.0 | 16.0 | 325.0% | |
| Foreign collaborators | % | 0.0 | 20.8 | - | |
| Indian inst/Mut Fund | % | 11.8 | 12.2 | 96.7% | |
| FIIs | % | 19.0 | 23.7 | 80.2% | |
| ADR/GDR | % | 0.0 | 1.1 | - | |
| Free float | % | 17.2 | 26.2 | 65.6% | |
| Shareholders | 31,796 | 161,166 | 19.7% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DIVIS LABORATORIES With: ORCHID PHARMA LTD STERLING BIOTECH ASTRAZENECA PHARMA VENUS REMEDIES IPCA LABS
Compare DIVIS LABORATORIES With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)
After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.
Related Views on News
CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)
Aug 10, 2018 | Updated on Aug 10, 2018For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.
DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)
Aug 6, 2018 | Updated on Aug 6, 2018For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)
Nov 10, 2017Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.
Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)
Oct 30, 2017Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)
Sep 12, 2018Is the pharma sector poised for a comeback? Is the worst over? I believe so.
Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)
Sep 12, 2018Richa has discovered the single most profitable opportunity in the market - read on to discover more...
The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)
Sep 7, 2018The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.
Should You Be Worried About the Rising Dollar?(Chart Of The Day)
Sep 7, 2018While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.
Revenge of the Ratings Agencies(Vivek Kaul's Diary)
Sep 7, 2018Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.
More|
| |
DIVIS LABORATORIES SHARE PRICE
Sep 19, 2018 (Close)
TRACK DIVIS LABORATORIES
- Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DIVIS LABORATORIES
DIVIS LABORATORIES 5-YR ANALYSIS
COMPARE DIVIS LABORATORIES WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.